ATE166389T1 - Ribotoxine, deren konjugate und pharmazeutische zusammensetzung - Google Patents

Ribotoxine, deren konjugate und pharmazeutische zusammensetzung

Info

Publication number
ATE166389T1
ATE166389T1 AT92306509T AT92306509T ATE166389T1 AT E166389 T1 ATE166389 T1 AT E166389T1 AT 92306509 T AT92306509 T AT 92306509T AT 92306509 T AT92306509 T AT 92306509T AT E166389 T1 ATE166389 T1 AT E166389T1
Authority
AT
Austria
Prior art keywords
cys
ribotoxins
restrictocin
cysteine
linkage
Prior art date
Application number
AT92306509T
Other languages
English (en)
Inventor
John Edward Fitton
David Timms
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919116011A external-priority patent/GB9116011D0/en
Priority claimed from GB919116000A external-priority patent/GB9116000D0/en
Priority claimed from GB919116002A external-priority patent/GB9116002D0/en
Priority claimed from GB919115999A external-priority patent/GB9115999D0/en
Priority claimed from GB919116001A external-priority patent/GB9116001D0/en
Priority claimed from GB929207488A external-priority patent/GB9207488D0/en
Priority claimed from GB929208397A external-priority patent/GB9208397D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ATE166389T1 publication Critical patent/ATE166389T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
AT92306509T 1991-07-24 1992-07-16 Ribotoxine, deren konjugate und pharmazeutische zusammensetzung ATE166389T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB919116011A GB9116011D0 (en) 1991-07-24 1991-07-24 Proteins
GB919116000A GB9116000D0 (en) 1991-07-24 1991-07-24 Proteins
GB919116002A GB9116002D0 (en) 1991-07-24 1991-07-24 Proteins
GB919115999A GB9115999D0 (en) 1991-07-24 1991-07-24 Proteins
GB919116001A GB9116001D0 (en) 1991-07-24 1991-07-24 Proteins
GB929207488A GB9207488D0 (en) 1992-04-06 1992-04-06 Proteins
GB929208397A GB9208397D0 (en) 1992-04-16 1992-04-16 Proteins

Publications (1)

Publication Number Publication Date
ATE166389T1 true ATE166389T1 (de) 1998-06-15

Family

ID=27562864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92306509T ATE166389T1 (de) 1991-07-24 1992-07-16 Ribotoxine, deren konjugate und pharmazeutische zusammensetzung

Country Status (14)

Country Link
US (1) US5439815A (de)
EP (1) EP0524768B1 (de)
JP (1) JPH05292960A (de)
AT (1) ATE166389T1 (de)
AU (1) AU654563B2 (de)
CA (1) CA2070751A1 (de)
CZ (1) CZ231292A3 (de)
DE (1) DE69225539T2 (de)
FI (1) FI923311A7 (de)
HU (1) HUT66110A (de)
IE (1) IE922135A1 (de)
IL (1) IL102389A0 (de)
NO (1) NO922933L (de)
SK (1) SK231292A3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248606A (en) * 1990-06-11 1993-09-28 Dowelanco Dna encoding inactive precursor and active forms of maize ribosome inactivating protein
GB9304905D0 (en) * 1992-03-16 1993-04-28 Zeneca Ltd Processes
IT1286663B1 (it) * 1996-06-27 1998-07-15 Ministero Uni Ricerca Scient E Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
US6262231B1 (en) * 1998-03-24 2001-07-17 Council Of Scientific And Industrial Research Polypeptides useful for diagnosis of Aspergillus fumigatus and a process of preparing the same
ES2241383B2 (es) * 2002-03-08 2008-04-01 Universidad Complutense De Madrid Metodo de produccion de variantes de ribotoxina.
US6878531B1 (en) * 2003-11-10 2005-04-12 Medical College Of Georgia Research Institute Method for multiple site-directed mutagenesis
CN101371140B (zh) * 2006-03-09 2013-11-13 弗·哈夫曼-拉罗切有限公司 抗药物抗体的测定
WO2014158770A1 (en) * 2013-03-14 2014-10-02 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
WO2017053290A1 (en) * 2015-09-23 2017-03-30 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3104208A (en) * 1963-09-17 Restkictocin
US3104204A (en) * 1960-07-11 1963-09-17 Michigan State Alpha sarcin
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
WO1988007578A1 (en) * 1987-04-02 1988-10-06 Genentech, Inc. Substrate assisted catalysis
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
ES2154627T3 (es) * 1988-08-24 2001-04-16 American Cyanamid Co Estabilizacion de somatotropinas mediante la modificacion de restos de cisteina utilizando mutagenesis de localizacion dirigida o derivatizacion quimica.
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
JP2518732B2 (ja) * 1990-02-22 1996-07-31 株式会社大塚製薬工場 α―サルシン遺伝子
GB9304905D0 (en) * 1992-03-16 1993-04-28 Zeneca Ltd Processes

Also Published As

Publication number Publication date
IE922135A1 (en) 1993-01-27
HUT66110A (en) 1994-09-28
AU654563B2 (en) 1994-11-10
EP0524768A2 (de) 1993-01-27
FI923311A0 (fi) 1992-07-20
FI923311L (fi) 1993-01-25
US5439815A (en) 1995-08-08
DE69225539D1 (de) 1998-06-25
CA2070751A1 (en) 1993-01-25
AU1866892A (en) 1993-01-28
HU9202343D0 (en) 1992-10-28
CZ231292A3 (en) 1993-04-14
EP0524768B1 (de) 1998-05-20
SK231292A3 (en) 1995-03-08
NO922933L (no) 1993-01-25
JPH05292960A (ja) 1993-11-09
IL102389A0 (en) 1993-01-14
NO922933D0 (no) 1992-07-23
FI923311A7 (fi) 1993-01-25
EP0524768A3 (de) 1994-02-09
DE69225539T2 (de) 1998-10-22

Similar Documents

Publication Publication Date Title
DE3687779D1 (de) Trichotecenkonjugate.
EA200301159A1 (ru) Цитотоксические иммуноконъюгаты антитела к cd44
ATE470714T1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
FR2437213A1 (fr) Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
MY108519A (en) Novel antibodies reactive with human carcinomas.
DE3774274D1 (de) Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen.
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
FI902245A0 (fi) Nytt antikroppsdistributionssystem foer modifierare av biologisk respons.
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
EP1469065A4 (de) Zusammensetzung eines spezifisch an cd20 bindenden antikörpers
BR0010721A (pt) Composições de neisserias combinadas
DE69225539D1 (de) Ribotoxine, deren Konjugate und pharmazeutische Zusammensetzung
MY131553A (en) Lyophilized formulation of polyethylene oxide modified proteins with increased self-life
PT85317A (fr) Procede pour l:obtention d:imunotoxines par couplage d:un anticorps avec une proteine trichosanthine ou trickokirine
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
FR2701710B1 (fr) Conjugués protéiques, compositions les contenant et leurs applications en tant que médicament et réactif de diagnostic.
DK0423818T3 (da) Arylsulfatase
WO1998051792A8 (en) Fac molecules and uses thereof